October 21, 2024
AMSTERDAM — The monoclonal antibody nemolizumab offers long-term efficacy and safety, as well as quality-of-life benefits, in the management of adolescents and adults with moderate to […]
October 18, 2024
AMSTERDAM — Treatment with ruxolitinib cream, 1.5%, achieved rapid and marked reductions in the clinical signs and symptoms of cutaneous lichen planus, including itch and skin […]
October 18, 2024
AMSTERDAM — Janus kinase inhibitors (JAKis) do not appear to increase the risk for major adverse cardiovascular events (MACE) among people with atopic dermatitis (AD) treated […]
October 17, 2024
AMSTERDAM — A new serum containing 2-mercaptonicotinoyl glycine (Melasyl) as its main ingredient was at least as good as, if not better than, cysteamine 5% cream […]
October 16, 2024
AMSTERDAM — Children with short stature related to severe atopic dermatitis (AD) not only can have their condition effectively treated with 16 weeks of dupilumab but […]
October 16, 2024
TOPLINE: Genetic susceptibility to hidradenitis suppurativa (HS) is linked to an increased risk for coronary artery disease (CAD) and diabetes, according to a cohort study, which […]
October 16, 2024
TOPLINE: Anti-BP180 antibody levels demonstrated a moderate to strong correlation with the severity of bullous pemphigoid (BP), in a meta-analysis highlighting the potential of anti-BP180 as […]
October 16, 2024
TOPLINE: White patients have the highest absolute risk for a second primary melanoma, while Black and Asian or Pacific Islander patients have the highest relative risk […]
October 11, 2024
TOPLINE: The retinoid alitretinoin is superior to phototherapy for rapidly alleviating severe chronic eczema of the hands and nets better compliance, albeit with a higher rate […]